Press Releases

2013      2012      2011      2010      2009     

Oct 17, 2013
Discovery Labs Announces IND Submission for AEROSURF® Click here for the webcast

Oct 8, 2013
Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the AEROSURF® Development Program

Oct 4, 2013
Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) Updated Product Specifications

Sep 05, 2013
Discovery Labs to Present at Stifel Healthcare Conference 2013

Aug 8, 2013
Discovery Labs Reports Second Quarter 2013 Financial Results Click here to listen

Jul 25, 2013
Discovery Labs to Report Second Quarter 2013 Results and HoldConference Call on Thursday, August 8, 2013

Jun 11, 2013
Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs

Jun 10, 2013
Discovery Labs Responds to FDA Request for Clarification of Recently Submitted SURFAXIN® (lucinactant) Updated Product Specifications

May 15, 2013
Discovery Labs Announces Completion of $14.25 Million Public Offering

May 10, 2013
Discovery Labs Prices $14.25 Million Public Offering of Common Stock

May 9, 2013
Discovery Labs Announces Proposed Public Offering of Common Stock

May 7, 2013
Discovery Labs Reports First Quarter 2013 Financial Results

May 1, 2013
Discovery Labs Announces Recent AFECTAIR® Publications

Apr 15, 2013
Discovery Labs Receives FDA Recommendations and Request for Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications

Mar 29, 2013
Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications

Mar 13, 2013
Discovery Labs Reports Fourth Quarter 2012 Financial Results Click here to listen

Mar 6, 2013
Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013

Feb 13, 2013
Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management

Jan 17, 2013
Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations

Jan 4, 2013
Discovery Labs Announces Changes to Board of Directors and Appoints a New Chief Executive Officer

Jan 3, 2013
Discovery Labs Initiates Launch of AFECTAIR®

The press releases and information stored here shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. To the extent that statements in the press releases and information stored here are not strictly historical, including statements as to the Company's business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in these releases are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect the Company's actual results and could cause  results to differ from those contained in the forward-looking statements contained herein are the risk that financial conditions may change, the risk that the Company will not be able to raise additional capital or enter into additional collaboration agreements, risks relating to the progress of the Company's research and development and the development of competing therapies and/or technologies by other companies.  Those associated risks and others are further described in the Company's periodic filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-KSB, 8-K, 10-QSB and 10-Q, and amendments thereto.